摘要
基因重组型凝血因子Ⅷ(rFⅧ)代替血浆来源的FⅧ(pdFⅧ)治疗血友病甲是血友病治疗史上的一次革命,但仍存在难以令人完全满意的地方,而目前研制的二代rFⅧ即B区缺失型FⅧ具有的优点弥补了野生型rFⅧ的不足,必将促使患者的选择由pdFⅧ彻底转向rFⅧ。
The treatment of hemophilia A with recombinant coagulation factorⅧ(rFⅧ)replacing plasma-derivedⅧ(pdFⅧ)has revolutionized hemophilia A cure.The full-length rFⅧproducts,however have some disadvantages.Second gener-ation,B-domain-deleted rFⅧhas some obvious advantages and the potential to meet the cure needs.The patients would rather choice the rFⅧthan the pdFⅧfor the treatment of hemophilia A in the future.
出处
《生物技术通讯》
CAS
2002年第6期473-475,共3页
Letters in Biotechnology
关键词
凝血因子Ⅷ
应用
现状
血浆来源
重组型
研究进展
血友病
coagulation factorⅧ
plasma-derived coagulation factorⅧ
recombinant coagulation factorⅧ